Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer
NCT04360629Completed
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of tranexamic acid in ovarian cancer (3 arms). Primary endpoint: Operative and postoperative blood loss up to 8 days. Started Jun 2020; status: completed.
02
Drugs
tranexamic acid
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04360629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04360629.